论文部分内容阅读
目的:对重组人组织型纤溶酶原激酶衍生物(瑞通立)治疗S-T段抬高型心肌梗死的疗效进行分析研究。方法:选择我院在2013年6月——2016年6月期间所收治的共48例急性S-T段抬高心肌梗死的患者作为研究对象。比较使用重组人组织型纤溶酶原激酶衍生物与尿激酶间溶栓效果。结果:使用重组人组织型纤溶酶原激酶衍生物静脉溶栓治疗的溶栓成功率较高。结论:急性ST段抬高型心肌梗死患者在应用重组人组织型纤溶酶原激酶衍生物进行溶栓治疗效果优于尿激酶,值得临床推荐。
Objective: To investigate the therapeutic effect of recombinant human tissue plasminogen kinase (Ruitongli) on S-T elevation myocardial infarction. Methods: A total of 48 patients with acute S-T elevation myocardial infarction in our hospital from June 2013 to June 2016 were selected as the study subjects. Comparison between recombinant human tissue plasminogen kinase and urokinase thrombolytic effect. RESULTS: Thrombolysis with recombinant human tissue-type plasminogen kinase derivatives had a higher success rate of thrombolysis. Conclusion: Thrombolysis with recombinant human tissue plasminogen activator is superior to urokinase in patients with acute ST-segment elevation myocardial infarction, which is worthy of clinical recommendation.